Daxxify®

In Brief

Daxxify® is FDA approved to smooth moderate to severe lines between the brows. It is the only frown line treatment powered by a peptide.

The active ingredient in Daxxify® is a purified protein called botulinum toxin type A.

Applying Areas

Applying areas are lines between the brows.

Key Features

Daxxify® is unique because it’s the only frown line treatment formulated with a peptide. The peptide helps eliminate the need for human or animal products to stabilize the active ingredient, botulinum toxin A.

​​The peptide also enhances attachment of the active ingredient, acting like a magnet and making more toxin available to enter nerve cells. ​​The peptide formulation delivers outstanding results that are fast, last, and give a better look to the skin’s texture after treatment.

Results

Daxxify® kicks in quickly. You may see results as early as the next day after treatment, and typically within 2 days.

Results as early as the next day and typically within 2 days. At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Improves the appearance of skin texture versus before treatment. 64% of patients achieved an improvement in the appearance of skin texture at week 2 from a post hoc analysis of a Phase 2 clinical study with 60 patients.

Daxxify® is long lasting and keeps frown lines smoother with the convenience of as few as 2 treatments a year. At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment.

Additional Information

The safety and efficacy of DAXXIFY® is well established, with more than 20 years of research. In fact, DAXXIFY® has been studied in the largest-ever phase 3 clinical trial conducted for a frown line treatment and included more than 2,800 people across different ages and with different skin types. DAXXIFY® was studied in patients with varying skin types.